Moleculin Biotech, Inc. (NASDAQ:MBRX) Q4 2023 Earnings Call Transcript
Operator: Greetings, welcome to the Moleculin Biotech 2023 Year-End Conference Call and Webcast. [Operator Instructions] Please note, that this conference is being recorded.
Moleculin Biotech Inc. (MBRX)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Armistice Capital Steven Boyd | 213,827.8 | $2,753,247 | 0.03% | |
| 2. | Citadel Investment Group Ken Griffin | 4,310.1,333,333,333 | $55,497 | 0% | |
| 3. | Renaissance Technologies Jim Simons | 8,640 | $111,000 | +8% | 0% |
| 4. | Millennium Management Israel Englander | 0 | $0 | -100% | 0% |
| 5. | Sio Capital Michael Castor | 0 | $0 | -100% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $0.69 | 28,986 | Officer | 80,556 | 2023-12-26 | Filing | |
| $0.69 | 14,493 | Director | 14,660 | 2023-12-26 | Filing | |
| $0.69 | 188,404 | Officer, Director | 680,880 | 2023-12-26 | Filing | |
| $1.28 | 45,000 | Officer, Director | 409,890 | 2022-11-25 | Filing | |
| $1.15 | 22,500 | Officer, Director | 364,890 | 2022-11-21 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.70 | 100,000 | Large Shareholder, Officer, Director | 967,724 | 2017-08-16 | Filing | |
| $1.70 | 100,000 | Large Shareholder | 2,781,573 | 2017-08-16 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 72,008.133,333,333 | $927,177 | 0% | |
| 2. | 16,444.666,666,667 | $211,802 | 0% | |
| 3. | 12,594.933,333,333 | $162,172 | 0% | |
| 4. | 4,759.8 | $61,287 | 0% | |
| 5. | 3,573.0,666,666,667 | $46,007 | 0% |
News See All
Moleculin Biotech, Inc. (NASDAQ:MBRX) Q3 2023 Earnings Call Transcript
Operator: Greetings, and welcome to the Moleculin Biotech Third Quarter 2023 Conference Call and Webcast. [Operator Instructions] As a reminder, this conference is being recorded.
Moleculin Biotech, Inc. (NASDAQ:MBRX) Q2 2023 Earnings Call Transcript
Operator: Hello, and welcome to the Moleculin Biotech Quarterly Update Conference Call and Webcast. [Operator Instructions] As a reminder, this conference is being recorded.
Moleculin Biotech, Inc. (NASDAQ:MBRX) Q1 2023 Earnings Call Transcript
Operator: Hello and welcome to the Moleculin Biotech Q1 2023 Quarterly Update Conference Call and Webcast. A question-and-answer session will follow the formal presentation.
Moleculin Biotech, Inc. (NASDAQ:MBRX) Q4 2022 Earnings Call Transcript
Operator: Hello and welcome to the Moleculin Biotech Fiscal Year 2022 Quarterly Update Conference Call and Webcast. A question-and-answer session will follow the formal presentation.
13G Filing: Sabby Capital and Moleculin Biotech Inc (MBRX)
Sabby Healthcare Master Fund, Ltd | 0 | 0 | 0 | 0 | 0 | 0 12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) CO CUSIP No. 60855D101 1. NAME OF REPORTING PERSONS Sabby Volatility Warrant Master Fund, Ltd.
Moleculin Biotech Inc (MBRX): Proceed With Caution
Moleculin Biotech Inc (NASDAQ:MBRX), an oncology-focused pharmaceutical firm that just joined public markets in June, is making some waves in the biotech world.